|Day Low/High||301.76 / 312.92|
|52 Wk Low/High||295.27 / 442.00|
RMPIA outperformed once gain during April.
Netflix is bullish, but faces key resistance before it can make a big run higher.
A low-risk countertrend options trade may be worth a look in this name.
In this day and age, companies must be 'disruptors' or get left in the dust.
So far 2019 is proving to be a year where things have a habit of working out right.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
These 'Bearish Bets' are showing both technical and quantitative deterioration.
Straying from these names could land you in quicksand as the 4th quarter begins.
It is all about perception, and here are strong names to pick up on market weakness.
An updated strategy for the high-flying REGN.
The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.
We have more evidence to support the bull case.
Stock still needs a period of base building to support advance.
Thanks to the stock market correction many world-class stocks are back down to attractive levels.
Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.
These favorite names in the volatile sector offer the potential for high rewards.
Traders and investors should stand aside until the situation with this biotech name offers a better entry point.
Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.
The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.
Many swings on a particular chart tend to be similar to others.
Shares have regained their 50-day moving average and look likely to push higher.